Quotes 5-day view Delayed Nasdaq
Net income 2020
Net Debt 2020
P/E ratio 2020
Net income 2021
Net Debt 2021
P/E ratio 2021
8 516 M
8 516 M
EV / Sales 2020
EV / Sales 2021
Nbr of Employees
BridgeBio Pharma, Inc. is discovering and developing medicines that target well-characterized genetic diseases. The Companyâ€™s product platform divided into three key categories: Mendelian, Oncology and Gene therapy. The Companyâ€™s pipeline programs include product candidates ranging from early discovery to late-stage development. The Companyâ€™s products include BBP-265, BBP-831, BBP-631 and BBP-454.
Notations Surperformance© of BridgeBio Pharma, Inc.
Trading Rating :
Investor Rating :
All news about BRIDGEBIO PHARMA, INC.
01/20 BRIDGEBIO PHARMA, INC. : Submission of Matters to a Vote of Security Holders, Ot..
01/20 BRIDGEBIO PHARMA : Stockholders of BridgeBio Pharma Inc and Eidos Therapeutics I..
01/19 Stockholders of BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Approve B..
01/19 miRagen Changes Name to Viridian; Names Jonathan Violin CEO, Barrett Katz Chi..
01/13 BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Announce January 21, 2021..
01/12 BRIDGEBIO PHARMA, INC. : Other Events (form 8-K)
01/07 BRIDGEBIO PHARMA : Director, Strategy & Transactions
01/06 BRIDGEBIO PHARMA : Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4..
01/05 BRIDGEBIO PHARMA : Leading Independent Proxy Advisory Firm ISS Recommends Bridge..
01/04 BRIDGEBIO PHARMA : Principal Accounting Officer Yi Ching Yau Steps Down
01/04 BRIDGEBIO PHARMA, INC. : Change in Directors or Principal Officers (form 8-K)
01/04 BRIDGEBIO PHARMA : Gets Proxy Advisory Firm Support For Merger With Eidos
01/04 Leading Independent Proxy Advisory Firm ISS Recommends BridgeBio Pharma and E..
2020 BRIDGEBIO PHARMA : UCSF Team Up to Accelerate Development of Therapeutics for Ge..
2020 UCSF and BridgeBio Pharma Collaborate to Accelerate the Development of Therap..
News in other languages on BRIDGEBIO PHARMA, INC.
- No features available -
Analyst Recommendations on BRIDGEBIO PHARMA, INC.
Chart BRIDGEBIO PHARMA, INC.
Technical analysis trends BRIDGEBIO PHARMA, INC.
Short Term Mid-Term Long Term Trends Neutral Bullish Bullish
Number of Analysts
Average target price
Last Close Price
Spread / Highest target
Spread / Average Target
Spread / Lowest Target